Presby Corp Appoints Burnham Financial Group as Its Investment Banker

Apr 26, 2001, 01:00 ET from Presby Corp

    DALLAS, April 26 /PRNewswire/ -- Presby Corp is pleased to announce the
 appointment of Burnham Financial Group (Burnham Securities, Inc. - NYSE) as
 its exclusive investment banker.  Burnham and its affiliate companies have a
 long history in corporate finance dating back to 1935.  Burnham will assist
 the Company in the evaluation of strategic alliances and in obtaining
 institutional growth capital.
     Presby Corp has developed the Scleral Expansion Band Procedure ("SRP") for
 the treatment of Presbyopia, Ocular Hypertension and Primary Open Angle
 Glaucoma ("POAG").  Presbyopia is the inability to focus at near and the
 primary reason that nearly everyone after their mid-40s uses bifocals, reading
 glasses or removes their distance glasses in order to read clearly.  Ocular
 Hypertension and POAG typically occur in patients that are presbyopic.  The
 Company believes that the SRP procedure physiologically restores the ability
 of the eye to accommodate or focus and physiologically lowers intraocular
 pressure in patients with Ocular Hypertension and POAG.  The SRP procedure
 utilizes a tiny implant device called a Scleral Expansion Band ("SEB") that is
 patented or patent pending virtually worldwide. The SEB device has been used
 in FDA Phase I clinical trials for the treatment of Presbyopia in the United
 States and in similar trials in Canada.  The Company expects to receive FDA
 approval to conduct clinical trials of the SEB in the United States for the
 treatment of Ocular Hypertension and POAG in the coming months.
     Presby Corp and its parent company, RAS Holding Corp, own multiple
 domestic and international patents directed to methods, devices and systems
 for the treatment of Presbyopia and other eye disorders, including Ocular
 Hypertension and Primary Open Angle Glaucoma.
     Presby Corp is based in Dallas, Texas.  For further information, visit the
 Company at www.presbycorp.com or contact Ronald A. Schachar, M.D., Ph.D.,
 Chairman & Chief Executive Officer, at 214/368-0200 (fax 214/368-0332) or
 email presby@presbycorp.com.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X80517469
 
 

SOURCE Presby Corp
    DALLAS, April 26 /PRNewswire/ -- Presby Corp is pleased to announce the
 appointment of Burnham Financial Group (Burnham Securities, Inc. - NYSE) as
 its exclusive investment banker.  Burnham and its affiliate companies have a
 long history in corporate finance dating back to 1935.  Burnham will assist
 the Company in the evaluation of strategic alliances and in obtaining
 institutional growth capital.
     Presby Corp has developed the Scleral Expansion Band Procedure ("SRP") for
 the treatment of Presbyopia, Ocular Hypertension and Primary Open Angle
 Glaucoma ("POAG").  Presbyopia is the inability to focus at near and the
 primary reason that nearly everyone after their mid-40s uses bifocals, reading
 glasses or removes their distance glasses in order to read clearly.  Ocular
 Hypertension and POAG typically occur in patients that are presbyopic.  The
 Company believes that the SRP procedure physiologically restores the ability
 of the eye to accommodate or focus and physiologically lowers intraocular
 pressure in patients with Ocular Hypertension and POAG.  The SRP procedure
 utilizes a tiny implant device called a Scleral Expansion Band ("SEB") that is
 patented or patent pending virtually worldwide. The SEB device has been used
 in FDA Phase I clinical trials for the treatment of Presbyopia in the United
 States and in similar trials in Canada.  The Company expects to receive FDA
 approval to conduct clinical trials of the SEB in the United States for the
 treatment of Ocular Hypertension and POAG in the coming months.
     Presby Corp and its parent company, RAS Holding Corp, own multiple
 domestic and international patents directed to methods, devices and systems
 for the treatment of Presbyopia and other eye disorders, including Ocular
 Hypertension and Primary Open Angle Glaucoma.
     Presby Corp is based in Dallas, Texas.  For further information, visit the
 Company at www.presbycorp.com or contact Ronald A. Schachar, M.D., Ph.D.,
 Chairman & Chief Executive Officer, at 214/368-0200 (fax 214/368-0332) or
 email presby@presbycorp.com.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X80517469
 
 SOURCE  Presby Corp